RAWALPINDI, Aug 28, 2026: The Drug Regulatory Authority of Pakistan (DRAP) has initiated the process of transitioning from the existing enlistment framework to a comprehensive licensing and registration regime for alternative medicines and health products, aimed at strengthening regulatory oversight and improving transparency in the sector.
According to an official communication issued by DRAP, the new rules are in the final stages of approval by the Federal Government. DRAP has also developed an integrated online portal for submission of licensing and registration applications.
The authority said the digital portal has been developed to simplify regulatory procedures, improve transparency and facilitate stakeholders in line with the government’s digitisation policy.
To familiarise manufacturers, importers and industry representatives with the new system, DRAP will hold an interactive orientation session at the Rawalpindi Chamber of Commerce and Industry (RCCI) on Monday, August 31, 2026.
The session will focus on stakeholders from Islamabad Capital Territory and Rawalpindi and will provide guidance on the new online portal and the transition from enlistment to the proposed licensing and registration framework.
Representatives of major industry associations, including the Homeopathic Pharmaceutical & Chemist Association Pakistan, Pakistan Tibbi Pharmaceutical Manufacturers Association, Nutraceutical Manufacturers Association of Pakistan and Pakistan Pharmaceutical Manufacturers Association, have also been invited.
The professionals believe the proposed regulatory transition is expected to strengthen standardisation, compliance and regulatory oversight of the alternative medicines and health-products sector, while introducing a more structured and digitally managed application process.
Fa
